Palliative concurrent chemoradiation for gastrostomy site metastasis P atients with head and neck squamous cell carcinoma typically present with dysphagia, odynophagia, and weight loss. Treatment of the disease with surgery or concurrent chemoradiation often results in local in ammation and limits further oral intake. Percutaneous endoscopic gastrostomy (PEG) has been a common and e ective means of nutritional support in these patients. An estimated 200,000 PEGs are performed annually in the United States, with head and neck cancer patients comprising up to 5% of those procedures.
Palliative concurrent chemoradiation for gastrostomy site metastasis P atients with head and neck squamous cell carcinoma typically present with dysphagia, odynophagia, and weight loss. Treatment of the disease with surgery or concurrent chemoradiation often results in local in ammation and limits further oral intake. Percutaneous endoscopic gastrostomy (PEG) has been a common and e ective means of nutritional support in these patients. An estimated 200,000 PEGs are performed annually in the United States, with head and neck cancer patients comprising up to 5% of those procedures. 1 A French retrospective study that evaluated a total of 139 consecutive patients treated for stage III-IV head and neck squamous cell carcinoma, showed that nutritional status at the end of treatment was unchanged from initial nutritional status in the PEG group. 2 In the same study, the cumulative incidence of treatment interruption from toxicity was signi cantly lower in the PEG group than in the no-PEG group (100 and 236 days of interruption, respectively, P = .03) and hospitalization was signicantly shorter in the PEG group (P = .003). In a retrospective review of 297 patients, Strom and colleagues reported independent risk factors for PEG tube placement in patients undergoing chemoradiation as the following: accelerated irradiation fractionation (odds ratio[OR], 4.3; 95% con dence interval [CI], 1.1-16.5; P = .04), a tumor T classication of 3 or higher (OR, 3.5; 95% CI, 1.0-11.9; P = .04), a cumulative cisplatin ≥200 mg/m² (OR, 6.7; 95% CI, 1.2-36.7; P = .03), and a body-mass index ≤25 kg/m 2 (OR, 5.8; 95% CI, 1.4-23.9; P = .02). 3 Although PEG has gained its wide acceptance as an e cient method of providing enteral nutrition in patients with head and neck carcinoma, PEG site metastasis remains a rare but valid concern. It was rst reported by Preyer and ul in 1989, 4 and the frequency is estimated to range from 0.5%-1%. 5 In this article, we report a case of PEG site metastasis with meaningful response to concurrent chemoradiation. We also discuss the common PEG insertion methods and the risks of metastasis, and review prevention and treatment strategies.
Case presentation and summary
A 54-year-old man with 40 pack-year smoking history presented with dysphagia and a weight loss of 20 lb over a year. An initial computed-tomography (CT) scan revealed a neoplasm at the right tonsil measuring 3.1 x 2.2 x 5.9 cm, involving the posterior pharynx and hypopharynx bilaterally and with necrotic contralateral level IIb lymphadenopathy. He underwent PEG using the GaudererPonsky (pull) technique simultaneously during the diagnostic laryngoscopy. e biopsy con rmed squamous cell carcinoma. He was treated with de nitive concurrent chemoradiation of 70 Gy in 35 fractions, with 2 cycles of cisplatin 100 mg/m 2 for stage IVA (T4N2cM0) oropharyngeal cancer, p16 negative.
A positron-emission tomography scan obtained 3 months after completion of therapy showed no evidence of active disease. However, 13 months after the completion of de nitive chemoradiation, the patient complained of pain and bleeding from the PEG site. Physical examination revealed no evidence of primary oropharyngeal cancer, but with a new 4- Misako Nagasaka, MD, a Takeshi Uemura, MD, b Jennifer L Harper, MD, c and Keisuke Shirai, MD, MSCR carcinoma was con rmed through a biopsy of this site. e paptient was also found to have concurrent liver metastases. His laboratory tests revealed normal values except for an albumin level of 3.2 g/dL and creatinine of 1.5 mg/dL. His Karnofsky Performance Status Scale score was 90 (range, 0-100; 0, dead and 100, normal; 90, minor signs or symptoms of disease but able to carry on normal activity). He then received palliative chemoradiation with weekly carboplatin at AUC 2 concurrently with 50.4 Gy in 28 fractions, followed with 10 Gy in 5 fractions boost electron radiation therapy focused at the PEG site to alleviate pain and control bleeding.
Several weeks afterward, pain and bleeding from the PEG site metastasis resolved. e visible portion of the PEG site metastasis signi cantly improved (Figure 2 ), thereby dramatically reducing local skin irritation and therefore improving the patient's quality of life. About 14 months after the completion of palliative concurrent chemoradiation, the PEG tube became dislodged because of stula formation. However, pain and bleeding was kept to a minimum until the patient died 21 months after the diagnosis of PEG site metastasis ultimately due to progression of disease.
Discussion

PEG tube insertion techniques
ere are 3 common techniques for PEG tube insertion. e rst 2, the Gauderer-Ponsky (pull) and the Russell (push) techniques, require passage of a exible endoscope through the esophagus and into the stomach. e third technique, the radiologically inserted gastrotomy (RIG), does not require use of an endoscope.
During the pull technique, a guidewire is inserted through the abdominal wall under endoscopic guidance. e gastrostomy tube is then secured to the transoral end of the wire and pulled through the patient's mouth and abdominal wall by pulling the extra-abdominal end of the wire. e push PEG technique is based on the Russell introducer method -after the endoscope is inserted and the PEG site is marked, a short guidewire is passed transabdominally and visualized with the endoscope. Serial dilators are passed over the guidewire to create a stoma tract, and the gastrostomy tube is pushed over the guidewire through the abdominal wall. 6 e RIG method is similar to the push technique but does not require endoscopy. RIG was rst described by Tao and Gillies in 1983. A nasogastric catheter is inserted and under uoroscopic observation the stomach is insu ated with air. A needle puncture is then performed through the anterior abdominal wall into the stomach and, following serial dilatation, the gastrostomy tube is inserted.
Mechanisms of PEG site metastasis
ere are several theories for the pathogenesis of PEG site metastasis. e most common cause of PEG site metastasis seems to be direct spread or seeding of the neoplasm during endoscopic procedure. Huang and colleagues have reported in a case series that 28 of 29 cases (96.6%) of PEG site metastasis in patients with PEG insertion reported the use of the Gauderer-Ponsky (pull ) technique. 7 Ellrichmann and colleagues performed a prospective study by evaluating the brush cytology of PEG tubing and transcutaneous incision immediately after PEG insertions. In that study, malignant cells were present in 22.5 % of patients immediately after pull-through PEG placement, 8 supporting the direct seeding pathogenesis.
Although PEG site metastasis is much more common with the Gauderer-Ponsky (push) technique, a case of puncture site metastasis in a radiologically inserted gastrostomy tube has been reported by Hawkin and colleagues. 9 Although the authors stated that the exact cause was unknown, they proposed consideration of hematogenous spread and/or the possibility of natural shedding of tumor cells. Brown and colleagues have supported the theory of hematogenous and or lymphatic spread of tumor cells.
10
Prevention and treatment of PEG site metastasis Most cases of PEG site metastasis that have been reported were performed using the Gauderer-Ponsky (pull) technique. Although not entirely safe, the RIG technique may be a better approach. Lin and colleagues have proposed that for patients with head and neck cancer, a barrier should be placed between the tumor and the instrumentation. However, they did not speci cally discuss the barrier. 11 Huang and colleagues have argued 89% of PEG site metastases in their case series occurred in patients who had undergone PEG before de nitive therapy and have suggested further research looking at the bene t of deferring PEG placement until after the initiation of radiotherapy or tumor resection. In their study, average time to death from detection of PEG metastasis was 5.9 months and 1-year survival after PEG metastasis was 35.5% with an overall mortality of 87.1%. 7 Given the grave prognosis, early detection is crucial. All patients with PEG should have their site examined at every visit.
In our case, PEG site metastasis was successfully brought under control with concurrent chemoradiation. Few case reports have documented chemoradiation as the treatment modality for PEG site metastasis. Adelson and colleagues reported a case of PEG site metastasis that was treated with 2 cycles of ifosfamide, paclitaxel, and carboplatin and abdominal wall radiation, which was without response. 12 Coletti and colleagues also reported a case of PEG site metastasis in which treatment with chemoradiation was initiated, but the patient decided to abort therapy after only a few treatments. 13 Potochny and colleagues reported a case of PEG site metastasis that was treated successfully with wide excision, 14 but often times, patients are not suitable surgical candidates by the time they are diagnosed with PEG site metastasis.
Although PEG site metastasis is a rare occurrence, it remains a concern. Pain and bleeding from PEG site metastasis can signi cantly decrease the quality of life for these patients, and their symptoms should be managed to the utmost. Chemoradiation provided a sustained response of local symptom control in our patient without signicant adverse e ects. e combination of chemotherapy and radiation therapy in patients with PEG site metastasis can be an e ective option as a potentially sustainable palliative strategy, signi cantly improving patient quality of life with minimal side e ects.
